Current diabetes reviews最新文献

筛选
英文 中文
Artificial Intelligence in Diabetes Mellitus Management: A Narrative Review of Advances, Architectures, and Translational Challenges. 糖尿病管理中的人工智能:进展、架构和转化挑战的叙述性回顾。
IF 2.6
Current diabetes reviews Pub Date : 2026-11-10 DOI: 10.2174/0115733998507302261019052129
Uriti Sri Venkatesh, Ankita Wal, Kumar Vimal, Sakshi Srivastava, Tushar Lokhande, Akanksha Singh, Mohd Javed Naim, Krishana Kumar Sharma, Amin Gasmi
{"title":"Artificial Intelligence in Diabetes Mellitus Management: A Narrative Review of Advances, Architectures, and Translational Challenges.","authors":"Uriti Sri Venkatesh, Ankita Wal, Kumar Vimal, Sakshi Srivastava, Tushar Lokhande, Akanksha Singh, Mohd Javed Naim, Krishana Kumar Sharma, Amin Gasmi","doi":"10.2174/0115733998507302261019052129","DOIUrl":"https://doi.org/10.2174/0115733998507302261019052129","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes Mellitus (DM), a chronic disorder caused by insulin deficiency, dysfunction, or both, is projected to affect 640 million people by 2040. Traditional management is limited by drug resistance, poor adherence, and insufficient personalization. This review examines Artificial Intelligence (AI) applications addressing these gaps in DM care.</p><p><strong>Methods: </strong>PubMed, Scopus, Web of Science, IEEE Xplore, and Google Scholar were searched (January 2020-December 2025) using combinations of diabetes mellitus, artificial intelligence, machine learning, deep learning, federated learning, explainable AI, and blockchain. Studies addressing AI-based risk prediction, glucose forecasting, complication detection, and secure or transparent frameworks were included, reported by diabetes subtype where relevant.</p><p><strong>Results: </strong>Convolutional neural networks, long short-term memory networks, support vector machines, and transformer architectures have improved glucose forecasting, complication screening, and risk prediction. Federated learning enables privacy-preserving multi-institutional training, while SHAP and LIME improve interpretability, and blockchain offers a tamper-proof audit layer. However, most high-performing models remain internally validated, limiting generalizability.</p><p><strong>Discussion: </strong>Unlike prior reviews that address a single application domain or treat T1DM and T2DM as a single population, this review is organized around their distinct AI design needs and classifies applications as experimental, commercial, or regulator-approved. AI can extend beyond technical accuracy by integrating diverse clinical data, though explainability and validation remain central to adoption.</p><p><strong>Conclusion: </strong>AI has the potential to transform DM care through more precise forecasting, earlier complication detection, and individualized treatment. Realizing this requires stronger regulatory frameworks, external validation, reduced demographic bias, and improved interpretability, prioritized through prospective multicenter studies, standardized datasets, and explainability standards embedded in clinical workflows.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic Syndrome and Early Cardiometabolic Risk Clustering in Patients with Type 1 Diabetes in Jazan, Saudi Arabia. 沙特阿拉伯吉赞市1型糖尿病患者的代谢综合征和早期心脏代谢风险聚类
IF 2.6
Current diabetes reviews Pub Date : 2026-11-05 DOI: 10.2174/0115733998515912261027062529
Omar Oraibi, Entsar Qadah, Mohammed Alshaikh, Faris A Alhazmi, Abdullah Khudier, Mohammed Zughlul, Mariam Tawhari, Norah Abdu Alhazmi, Abdulrahman Alqasem, Wali Ahmed Hakami, Abdulrahman Hummadi, Abdulrahman Mohammed Hakami, Mohammed Somaili, Mostafa Mohrag, Luai Alhazmi
{"title":"Metabolic Syndrome and Early Cardiometabolic Risk Clustering in Patients with Type 1 Diabetes in Jazan, Saudi Arabia.","authors":"Omar Oraibi, Entsar Qadah, Mohammed Alshaikh, Faris A Alhazmi, Abdullah Khudier, Mohammed Zughlul, Mariam Tawhari, Norah Abdu Alhazmi, Abdulrahman Alqasem, Wali Ahmed Hakami, Abdulrahman Hummadi, Abdulrahman Mohammed Hakami, Mohammed Somaili, Mostafa Mohrag, Luai Alhazmi","doi":"10.2174/0115733998515912261027062529","DOIUrl":"https://doi.org/10.2174/0115733998515912261027062529","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic syndrome (MetS) represents clustering of cardiometabolic risk factors in individuals with type 1 diabetes (T1D), yet data from Saudi Arabia remain limited. This study determined the prevalence of MetS and identified associated factors among patients with T1D in the Jazan region.</p><p><strong>Methods: </strong>This cross-sectional observational study included 91 patients with T1D attending the Jazan Endocrine and Diabetes Center between August 2023 and August 2024. Sociodemographic, clinical, anthropometric, and laboratory data were obtained through structured interviews and electronic medical records. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. Factors associated with MetS were evaluated using univariate and multivariable logistic regression analyses.</p><p><strong>Results: </strong>The prevalence of MetS was 25.3% (95% CI: 17.5-35.1%). Fasting plasma glucose ≥100 mg/dL was observed in 69.2% of participants, and reduced HDL-C in 65.9% of participants. Reduced HDL-C was more frequent in females than males (76.9% vs. 51.3%; p = 0.011), whereas elevated triglycerides were more common in males (17.9% vs. 3.8%; p = 0.035). Older age (aOR = 1.13; 95% CI: 1.02-1.25; p = 0.015) and a positive family history of diabetes or MetS (aOR = 5.57; 95% CI: 1.40-22.27; p = 0.015) were independently associated with MetS.</p><p><strong>Discussion: </strong>The observed prevalence of MetS and clustering of cardiometabolic abnormalities highlight the coexistence of multiple metabolic risk factors in this relatively young T1D population. These findings support comprehensive cardiometabolic risk assessment alongside glycemic management, although interpretation should consider the cross-sectional, single-center design and the operational definition of MetS used in this study.</p><p><strong>Conclusion: </strong>Among patients with T1D attending the Jazan Endocrine and Diabetes Center, approximately one-quarter met the criteria for MetS, demonstrating clustering of cardiometabolic risk factors in a relatively young population. Older age and a positive family history of diabetes or MetS were independently associated with MetS. Although cardiovascular outcomes were not assessed, the observed clustering of risk factors supports the need for comprehensive cardiometabolic risk assessment as part of T1D care.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of Atherogenic Index of Plasma in Diabetic Peripheral Neuropathy A Case Control Study. 糖尿病周围神经病变血浆动脉粥样硬化指数的临床意义:病例对照研究。
IF 2.6
Current diabetes reviews Pub Date : 2026-11-02 DOI: 10.2174/0115733998525366261024092418
Lashin S Ali, Mohamed Osama Mostafa, Dana Kh Alsharayiah, Hoda Abd Elwahab Fansa, Mohammed Ramadan, Hamada Zehry, Noran ElBazzar, Mohamed A Younes, Elsayed F Ali, Abdelazeem E Ahmed, Shimaa Mohamed Abd El-Kareem, Sherief El Ghannam, Tamer Mohamed Abd Elkader
{"title":"Clinical Significance of Atherogenic Index of Plasma in Diabetic Peripheral Neuropathy A Case Control Study.","authors":"Lashin S Ali, Mohamed Osama Mostafa, Dana Kh Alsharayiah, Hoda Abd Elwahab Fansa, Mohammed Ramadan, Hamada Zehry, Noran ElBazzar, Mohamed A Younes, Elsayed F Ali, Abdelazeem E Ahmed, Shimaa Mohamed Abd El-Kareem, Sherief El Ghannam, Tamer Mohamed Abd Elkader","doi":"10.2174/0115733998525366261024092418","DOIUrl":"https://doi.org/10.2174/0115733998525366261024092418","url":null,"abstract":"<p><strong>Background and aim: </strong>Diabetic peripheral neuropathy (DPN) is one of the most common and debilitating complications of diabetes mellitus (DM). The atherogenic index of plasma (AIP), calculated from triglyceride and high-density lipoprotein cholesterol levels, is an indicator of atherogenic lipid profile. The present study aimed to investigate the clinical significance of AIP in patients with DPN.</p><p><strong>Subjects and methods: </strong>This study included 200 patients with DM and 200 age- and sex-matched healthy controls. The diabetic patients comprised 100 patients with DPN and 100 patients without DPN. All participants underwent detailed history taking, thorough clinical examination, nerve conduction studies, and standard laboratory investigations.</p><p><strong>Results: </strong>AIP differed significantly among the three groups, with DPN patients having significantly higher AIp values than diabetic patients without DPN and healthy controls [median (IQR): 0.37 (0.21-0.52) vs. 0.24 (0.09-0.49) and 0.08 (-0.07-0.19), respectively; p<0.001]. Among patients with DPN, those with AIP ≥ the median had a significantly higher frequency of cardiovascular comorbidities (79.7% vs. 51.6%, p=0.008) and severe DPN (40.6% vs. 12.9%, p=0.018). ROC curve analysis showed that AIP had modest discriminatory ability for distinguishing patients with DPN from diabetic patients without DPN [AUC (95% CI): 0.63 (0.55-0.71)].</p><p><strong>Discussion: </strong>Patients with DPN had significantly higher AIP levels than diabetic patients without neuropathy and healthy controls. Among patients with DPN, higher AIP levels were associated with a greater frequency of severe neuropathy and cardiovascular comorbidities. These findings suggest an association between an atherogenic lipid profile and the presence and clinical characteristics of DPN, although the modest discriminatory performance of AIP indicates that it should not be considered a standalone diagnostic marker for DPN.</p><p><strong>Conclusion: </strong>Patients with DPN had significantly higher AIP levels than diabetic patients without neuropathy and healthy controls. Among patients with DPN, higher AIP levels were associated with more severe neuropathy and a higher frequency of cardiovascular comorbidities. Further studies are warranted to determine whether AIP has an independent or predictive role in DPN.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare Team Resilience and System Constraints in Diabetes Care: A Qualitative Study from the Dominican Republic. 糖尿病护理中的医疗团队弹性和系统约束:来自多米尼加共和国的定性研究。
IF 2.6
Current diabetes reviews Pub Date : 2026-10-28 DOI: 10.2174/0115733998510459261022092633
Amerigo Rossi, Mónica Ortiz Rossi, Aurelina Carrión Jiménez, Rosa Elena Torres-Panchame
{"title":"Healthcare Team Resilience and System Constraints in Diabetes Care: A Qualitative Study from the Dominican Republic.","authors":"Amerigo Rossi, Mónica Ortiz Rossi, Aurelina Carrión Jiménez, Rosa Elena Torres-Panchame","doi":"10.2174/0115733998510459261022092633","DOIUrl":"https://doi.org/10.2174/0115733998510459261022092633","url":null,"abstract":"<p><strong>Introduction: </strong>The growing prevalence of Type 2 Diabetes (T2D) places a significant burden on health care systems in Low- and Middle-Income Countries (LMICs) due to resource limitations. Better understanding of health care team perspectives regarding the barriers and facilitators in these settings will help develop sustainable, evidence-informed improvements that are necessary to meet the increasing need for diabetes care.</p><p><strong>Methods: </strong>This study explored the perceptions of providers, support staff, and administration of a regional diabetes clinic in the Dominican Republic that sees approximately 70 patients per week. Semi-structured interviews were conducted with all eleven clinic employees. Inductive thematic analysis was conducted to determine emergent themes.</p><p><strong>Results: </strong>Five interrelated themes emerged: 1) Moral orientation towards patient care; 2) Resource scarcity; 3) Time and educational constraints; 4) Outdated equipment and systems; 5) Limitations in infrastructure accessibility. Participants consistently stated that they see their job as more of a calling and must take on additional responsibilities to help provide the quality care the patients require. Constrained clinic resources and infrastructure led to significant inefficiencies, and the lack of a diabetes educator limited medical provider capacity.</p><p><strong>Discussion: </strong>These findings suggest that healthcare team resilience helps sustain diabetes care under resource constraints, but reliance on individual adaptations may threaten long-term sustainability in the absence of system-level investment.</p><p><strong>Conclusion: </strong>Targeted, low-cost improvements, low-burden programming, and structured patient education may strengthen long-term diabetes care delivery in LMIC clinics.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic Insights into GLP-1 and DPP-4 Pathways: Opportunities for Nano-Delivery and β-Cell Protection and Regeneration. GLP-1和DPP-4途径的机制见解:纳米递送和β-细胞保护和再生的机会。
IF 2.6
Current diabetes reviews Pub Date : 2026-10-21 DOI: 10.2174/0115733998510084261013134755
Muhammad Raza, Jun-Sub Kim, Hyang-Yeol Lee
{"title":"Mechanistic Insights into GLP-1 and DPP-4 Pathways: Opportunities for Nano-Delivery and β-Cell Protection and Regeneration.","authors":"Muhammad Raza, Jun-Sub Kim, Hyang-Yeol Lee","doi":"10.2174/0115733998510084261013134755","DOIUrl":"https://doi.org/10.2174/0115733998510084261013134755","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction/objective: &lt;/strong&gt;Diabetes mellitus is characterized by persistent hyperglycemia and progressive β-cell dysfunction. GLP-1 receptor agonists improve glycemic control and weight management, with cardiovascular and renal benefits reported in some patients, while DPP-4 inhibitors generally have more modest effects. Limitations such as peptide instability, administration challenges, tolerability, cost, and long-term treatment burden have encouraged the development of advanced drug-delivery and regenerative strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This narrative review evaluates the molecular mechanisms of GLP-1 and DPP-4 signaling and the therapeutic potential of emerging approaches for diabetes management. The literature was reviewed with particular emphasis on nanotechnology-based drug-delivery systems, geneand mRNA-based therapies, and cell-based strategies for incretin therapy, β-cell preservation, and regeneration. Evidence regarding therapeutic efficacy, delivery-system characteristics, development status, advantages and limitations, and barriers to clinical translation was critically examined to provide an integrated overview of current advances and future opportunities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;GLP-1 signaling and DPP-4 inhibition improve glucose-dependent insulin secretion while supporting β-cell survival and function. Nanotechnology-based delivery systems show potential to improve peptide stability, bioavailability, controlled release, and tissue targeting, although most approaches remain at the preclinical stage. Gene, mRNA, and cell-based approaches have shown β-cell regeneration or preservation in animal models; however, clinically meaningful endogenous β-cell regeneration has not yet been established in humans. Key barriers to clinical translation include long-term biosafety, immunogenicity, manufacturing scalability and reproducibility, regulatory requirements, cost, and clinical implementation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;Combining cutting-edge delivery technologies with well-established incretin pharmacology may help overcome some of the drawbacks of conventional treatments. However, nano-delivery, gene, mRNA, and regeneration techniques are still in preclinical or early research stages; they should be clearly distinguished from clinically proven treatments. To determine their longterm efficacy, safety, and clinical value, more validation in well-organized clinical trials is needed..&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;GLP-1 receptor agonists and DPP-4 inhibitors remain established components of incretin- based therapy, while advanced nanotechnology-based delivery systems offer promising opportunities but are largely supported by preclinical evidence. Future research should highlight the combination of precision medicine, pharmacogenomics, artificial intelligence-assisted treatment, and optimized drug-delivery systems to improve therapeutic efficacy and patient-specific outcomes. Smart glucos","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gliflozin-Derived SGLT2 Inhibitors: Recent Advances and Future Perspectives in the Management of Type 2 Diabetes. 格列净衍生的SGLT2抑制剂:在2型糖尿病治疗中的最新进展和未来展望
IF 2.6
Current diabetes reviews Pub Date : 2026-10-13 DOI: 10.2174/0115733998505609261006104914
Biswanath Prusty, Sudhansu Sekhar Rout, Abhijit Saha
{"title":"Gliflozin-Derived SGLT2 Inhibitors: Recent Advances and Future Perspectives in the Management of Type 2 Diabetes.","authors":"Biswanath Prusty, Sudhansu Sekhar Rout, Abhijit Saha","doi":"10.2174/0115733998505609261006104914","DOIUrl":"https://doi.org/10.2174/0115733998505609261006104914","url":null,"abstract":"<p><p>Gliflozin derivatives, a class of Sodium-Glucose Cotransporter (SGLT) inhibitors, have emerged as effective antidiabetic agents offering notable cardiovascular and renal protection. This class of compounds inhibits glucose reabsorption in the kidneys, thereby improving overall glycaemic control. This review provides a comprehensive overview of gliflozin derivatives, emphasizing their chemical characterization, safety, therapeutic efficacy, pharmacokinetic analysis, and potential future applications, focusing on clinical trials and new developments released between 2010 and 2026. Gliflozin derivatives slow the progression of chronic kidney disease and reduce the risk of heart failure. Some preliminary experimental evidence has reported the antibacterial activity of canagliflozin against MRSA. The Gliflozin derivatives dapagliflozin (IC50 =1.1nM), ertugliflozin (IC50 =0.9nM), sotagliflozin (IC50 =1.8nM), and bexagliflozin (IC50 =2.3nM), which has core motif, 1-chloro-2-(4-alkoxy benzyl) benzene as an aglycon unit and a glycon unit bind with SGLT2 receptor and lowered the HbA1c by 1.2%, 1.7%, 0.41% and 0.80%, respectively. Its selectivity, pharmacokinetics, and toxicity profiles are also optimal. Recent studies have demonstrated their involvement in conditions other than diabetes, including obesity, non-alcoholic fatty liver disease, Cardioprotective, Nephroprotective, Anti-inflammatory, and antihypertensive effects. Gliflozin derivatives represent a paradigm shift in the management of diabetes and have broad therapeutic potential. Future studies should emphasize creative structural changes to increase safety and efficacy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronotherapeutic and Circadian Rhythm-Based Strategies in Diabetes Management: A Critical Opinion Based on Evidences. 以时间治疗和昼夜节律为基础的糖尿病管理策略:基于证据的批评意见。
IF 2.6
Current diabetes reviews Pub Date : 2026-10-12 DOI: 10.2174/0115733998495346261007070830
Vijay Singh, Neeraja Suresh, Sapna Saini, Shailendra Dwivedi, Akash Bansal
{"title":"Chronotherapeutic and Circadian Rhythm-Based Strategies in Diabetes Management: A Critical Opinion Based on Evidences.","authors":"Vijay Singh, Neeraja Suresh, Sapna Saini, Shailendra Dwivedi, Akash Bansal","doi":"10.2174/0115733998495346261007070830","DOIUrl":"https://doi.org/10.2174/0115733998495346261007070830","url":null,"abstract":"<p><p>Diabetes mellitus is one of the world's leading health problems, and standard approaches to therapy do not take into consideration the impact of circadian misalignment on metabolic health. Chronobiological processes are involved in regulating glucose homeostasis, insulin release, hepatic glucose production, lipids, and energy metabolism; hence, disruptions such as those caused by non-rhythmic sleep patterns, shifts at work, irregular meal times, and light exposure could cause insulin resistance and even type 2 diabetes. The current critical review discusses the light-melatonin interaction and personalized chronobiological medicine. Instead of giving a descriptive account of particular treatments, the paper introduces the integrative importance of chronobiology for the management of diabetes by considering data about chrononutrition, time-restricted feeding, chronopharmacology, chrono-exercise, and an approach to chronometabolism based on the integration of the timing of meals, drugs, exercise, sleep, and light exposure with chronotype, metabolic phenotype, and the feasibility of the therapy. Circadian timing can be a promising adjuvant in the treatment of diabetes; however, the available evidence does not suggest an ideal time for intervention. Further studies should focus on measuring time, well-powered randomized controlled trials, long-term outcomes, and individualization of chronotherapy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing Artificial Intelligence-driven Approaches in the Diagnosis and Management of Diabetes and Diabetes-Associated Complications. 利用人工智能驱动的方法诊断和管理糖尿病和糖尿病相关并发症。
IF 2.6
Current diabetes reviews Pub Date : 2026-10-05 DOI: 10.2174/0115733998484763260928100503
Yachana Mishra, Rajeev Kanday, Simran Kauts, Sheetu Wadhwa, Aditi Chattaraj, Alaa A A Aljabali, Altijana Hromić-Jahjefendić, Vladimir N Uversky, Vijay Mishra
{"title":"Harnessing Artificial Intelligence-driven Approaches in the Diagnosis and Management of Diabetes and Diabetes-Associated Complications.","authors":"Yachana Mishra, Rajeev Kanday, Simran Kauts, Sheetu Wadhwa, Aditi Chattaraj, Alaa A A Aljabali, Altijana Hromić-Jahjefendić, Vladimir N Uversky, Vijay Mishra","doi":"10.2174/0115733998484763260928100503","DOIUrl":"https://doi.org/10.2174/0115733998484763260928100503","url":null,"abstract":"<p><p>Diabetes mellitus is a global health issue with escalating metabolic dysfunction, clinical heterogeneity, and rising microvascular and macrovascular consequences. Traditional diabetes diagnosis, risk assessment, treatment selection, and complication surveillance rely on periodic clinical measures and population-level risk models, which may not fully capture dynamic, individualized disease pathways. Precision diabetes treatment is being transformed by Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and multimodal data analytics. This review critically examines AI-driven approaches to diabetes management, including early disease prediction, diagnostic support, glycemic monitoring, treatment-response prediction, and the prevention and detection of diabetes-associated complications. The US Food and Drug Administration (USFDA) has sanctioned multiple AI/ML-based medical devices for automated retinal screening, clinical diagnostic assistance, and patient self-management applications. For clinically meaningful patterns and disease progression prediction, AI-enabled analysis of continuous glucose monitoring data, retinal images, electronic health records, wearable device signals, laboratory parameters, and multi-omics datasets is prioritized. The use of AI for detecting diabetic retinopathy, kidney disease, cardiovascular disease, neuropathy, and foot disorders is also highlighted.Data quality, algorithmic bias, interpretability, privacy, cybersecurity, model drift, regulatory monitoring, clinical validation, and equitable access prevent widespread application despite promising results. This study offers a thorough and critical assessment of the developing roles of AI, specifically ML and DL, in the prediction, diagnosis, and management of diabetes and its related complications. Real-world validation, standardized evaluation frameworks, trustworthy AI, and effective human- AI collaboration will drive advancement. AI could transform diabetes management into predictive, tailored, continuous, and complication-preventive care.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Metformin on Thyroid Function in Patients with Type 2 Diabetes, Subclinical Hypothyroidism, and Insulin Resistance: A Systematic Review and Meta-Analysis. 二甲双胍对2型糖尿病、亚临床甲状腺功能减退和胰岛素抵抗患者甲状腺功能的影响:系统回顾和荟萃分析
IF 2.6
Current diabetes reviews Pub Date : 2026-09-29 DOI: 10.2174/0115733998496363260914080851
Hossein Nezami, Alireza Amirabadizadeh, Mahdi Abdesheikhi, Ahmadreza Baghestani, Habibollah Esmaily
{"title":"Effects of Metformin on Thyroid Function in Patients with Type 2 Diabetes, Subclinical Hypothyroidism, and Insulin Resistance: A Systematic Review and Meta-Analysis.","authors":"Hossein Nezami, Alireza Amirabadizadeh, Mahdi Abdesheikhi, Ahmadreza Baghestani, Habibollah Esmaily","doi":"10.2174/0115733998496363260914080851","DOIUrl":"https://doi.org/10.2174/0115733998496363260914080851","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Metformin, the first-line therapy for type 2 diabetes and insulin resistance, has been reported to affect thyroid function, particularly Thyrotropin (TSH), although results for other thyroid hormones are inconsistent. We therefore performed a systematic review and meta-analysis to evaluate the effects of metformin on serum TSH, FT4, FT3, total T4, and total T3 levels compared with placebo in patients with type 2 diabetes, insulin resistance, and subclinical hypothyroidism.</p><p><strong>Methods: </strong>A systematic search of PubMed, Scopus, Web of Science, and Google Scholar was conducted from inception to November 2025 to identify randomized controlled trials and observational studies evaluating the effects of metformin on thyroid hormone parameters compared with placebo. Pooled mean differences with 95% confidence intervals were calculated using random-effects models. Heterogeneity was assessed using the I2 statistic, and publication bias was evaluated using Begg's test. Sensitivity analyses were performed to assess the robustness of the pooled estimates.</p><p><strong>Results: </strong>A total of 13 studies including 1,178 participants were included in the meta-analysis. In patients with type 2 diabetes, metformin therapy was associated with a statistically significant reduction in serum FT3 concentrations compared with placebo (MD= -0.44; 95% CI: -0.79 to -0.10; p = 0.01), whereas no significant change in serum TSH levels was observed (MD = -0.38; 95% CI: -1.05 to 0.41; p = 0.39); FT4 and total T4 levels also remained unchanged. Among patients with subclinical hypothyroidism, metformin treatment was not associated with significant changes in TSH or FT4 concentrations.</p><p><strong>Discussion: </strong>Metformin appears to have limited effects on thyroid-related parameters in patients with type 2 diabetes and subclinical hypothyroidism. The observed reduction in FT3 levels, in the absence of consistent changes in TSH or FT4, may indicate that the changes observed in thyroid hormone profiles are limited and should be interpreted considering the clinical context and variability among included studies.</p><p><strong>Conclusion: </strong>Current evidence suggests that metformin does not significantly modify overall thyroid function in patients with type 2 diabetes, subclinical hypothyroidism, or insulin resistance. Further studies are needed to clarify its potential effects in specific patient populations.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Pediatric Glycemic Control with Smart Insulin Pens: The Current Trends and Future Prospects. 用智能胰岛素笔改善儿童血糖控制:当前趋势和未来前景。
IF 2.6
Current diabetes reviews Pub Date : 2026-09-25 DOI: 10.2174/0115733998468232260917101115
Hadia Hannan, Fares Mohammad, Khaled Chahrour, Banan Mohgoub, Nour M Al Sawaftah, Kelly M Percival, Ghaleb A Husseini
{"title":"Improving Pediatric Glycemic Control with Smart Insulin Pens: The Current Trends and Future Prospects.","authors":"Hadia Hannan, Fares Mohammad, Khaled Chahrour, Banan Mohgoub, Nour M Al Sawaftah, Kelly M Percival, Ghaleb A Husseini","doi":"10.2174/0115733998468232260917101115","DOIUrl":"https://doi.org/10.2174/0115733998468232260917101115","url":null,"abstract":"<p><p>Pediatric diabetes management remains challenging, as many young patients struggle to hit glycemic targets due to developmental factors and treatment burdens. Smart insulin pens are a game-changing \"connected MDI\" alternative, with \"pump-like\" features such as bolus calculators and automated Insulin-on-Board tracking for non-pump users. This review explores the clinical effectiveness, economic impact, and prospects of SIPs in pediatrics, including patient and caregiver insights and long-term effects on glycemic control. Caregivers and patients agree SIPs are accessible and easy to use due to user-friendly interfaces, data-driven approaches, and remote monitoring. Evidence shows SIPs improve safety and adherence, with a 31.4% reduction in daily hypoglycemia, a 24.4% decrease in nocturnal hypoglycemia, and a drop in Time Below Range Level 2 from 2.82% to 2.18%. By tracking insulin-on-board, SIPs prevent insulin stacking and enable safe correction doses; users correcting within three hours of a previous dose spend more time in range without increased hypoglycemia. SIPs also cut missed boluses by up to 43% in youth. Economically, SIPs save about SEK 124,270 per patient by delaying complications. However, adoption remains limited due to socioeconomic barriers, with 82% of clinics citing insurance issues and lower use among Medicaid beneficiaries. Barriers include the learning curve and device costs, which can be addressed through subsidies and training programs. Future AI developments, like hypoglycemia prediction, promise to further personalize pediatric care. Overall, SIPs benefit pediatric diabetes management, but more research, including clinical trials, is needed to confirm optimal outcomes.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书